Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis

Sara Bringhen,Ludek Pour,Vladimir Vorobyev,Filiz Vural,Krzysztof Warzocha,Lotfi Benboubker,Youngil Koh,Vladimir Maisnar,Lionel Karlin,Michel Pavic,Frank Campana, Solenn Le Guennec,Fatima Menas,Helgi van de Velde,Paul G Richardson

Leukemia Research（2021）

引用 18|浏览14

暂无评分

摘要

•In ICARIA-MM, isatuximab-pomalidomide-dexamethasone (Isa-Pd) improved PFS in RRMM.•We assessed Isa-Pd versus Pd in RRMM by prior lines of therapy/refractory status.•Isa-Pd improved PFS in RRMM regardless of prior lines of therapy/refractory status.•Isa-Pd improved ORR in RRMM regardless of prior lines of therapy/refractory status.•Overall safety profile of Isa-Pd is manageable in RRMM patients.

查看译文

关键词

anti-CD38 monoclonal antibody,Isatuximab,Multiple myeloma,Prior lines,Relapsed,Refractory

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要